基于大剂量阿糖胞苷的巩固治疗方案用于首次完全缓解的存在中度细胞遗传学风险的老年急性粒细胞白血病患者时预后更佳

We evaluated outcomes in two consecutive groups of AML patients age > 60 years in CR after 7 + 3 induction therapy. Group 1 received consolidation with cytarabine 1.5 g/m2 q12 h × 6 + daunorubicin for two cycles, while group 2 received consolidation with 7 + 3 followed by mitoxantrone + etoposide. For patients with intermediate-risk cytogenetics, group 1 had a significantly superior DFS (p = 0.046), and a trend toward better OS (p = 0.087). The treatment group remained a significant predictor of DFS on multivariate analysis. The results indicate that a high-dose cytarabine-containing consolidation regimen produces superior outcomes in AML patients age > 60 years with intermediate-risk cytogenetics.